With the average uninsured cost of TKI treatment close to or above $146,000 per year per patient with CML in the United States, reducing or ending treatment would yield billions in savings.
The Supreme Court's ruling in the Amgen v Sandoz case may hasten the arrival of lower-cost biosimilar versions of biologics in the clinic, potentially saving billions of dollars in health care spending.
Cancer Therapy Advisor asked Filippo Montemurro, MD, to place recent findings in context with respect to when T-DM1 might be best indicated.
Vaccines targeting multiple myeloma antigens offer a promising therapeutic approach by helping the immune system to fight off cancer cells.
Several presentations demonstrated that abemaciclib provides clinical benefit for women with HR+/HER2-negative breast cancer who progress on or are resistant to endocrine therapy.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Dietary Nutrients and Oncogenic HPV Infections
- Vaccines Targeting Multiple Myeloma Offer Promising Therapeutic Approach
- In Focus: Abemaciclib for Advanced Breast Cancer
- Supreme Court Ruling Should Hasten Arrival of Biosimilars, But Uncertainties Remain
- FDA Expands Daratumumab Approval for Multiple Myeloma
- Yoga Improves Sleep Disorders, Fatigue in Patients With Cancer
- Aldoxorubicin Improves Outcomes in Relapsed/Refractory Sarcoma
- Cryosurgery: The Future of Breast Cancer Treatment?
- Nivolumab With Ipilimumab May Negate Need for Whole Brain Radiotherapy in Melanoma With Brain Metastases
- Green Tea and Cancer
- Favorable 4-year Outcomes for Patients With Myeloma Treated With Elotuzumab
- Patients With Hepatocellular Carcinoma May Benefit From TACE Plus Axitinib
- Evofosfamide Not Recommended in First-line Sarcoma Treatment
- TKI Discontinuation for Patients With CML Could Save Billions
- Midostaurin Plus Chemotherapy Prolongs Survival in AML With FTL3 Mutation